ENDOCARE RECEIVES FDA 510K CLEARANCE TO MARKET NEW NITROGEN-BASED CRYOABLATION SYSTEM FOR DESTROYING TISSUE AND CANCEROUS TUMORS

Endocare, Inc., an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced that it has received 510K clearance from the U.S. Food and Drug Administration to market its new Cryocare CN2 System, a potentially much faster and easier-to-operate cryoablation system for freezing cancerous tumors and tissue. This new system uses nitrogen as the freezing and tumor-destroying element. The nitrogen, called "critical nitrogen" because it works in a unique form at the critical point where gas nearly becomes liquid, is also more powerful and more readily available in surgical suites than argon, the freezing element in Endocare's current market-leading cryoablation systems.
Endocare